
Cingulate (CING) Stock Forecast & Price Target
Cingulate (CING) Analyst Ratings
Bulls say
Cingulate is a clinical stage biopharmaceutical company with a strong focus on developing treatments for ADHD and anxiety using its proprietary drug delivery platform technology. The recent $12 million raise puts the company in a comfortable cash position to fund its operations into mid-2027, providing a stable financial outlook. With a current valuation that we believe to be very attractive, coupled with positive results from its recent reports, we maintain a BUY rating for this company with a 12-month price target of $58, taking into account risks such as liquidity, product efficacy, and regulatory approvals.
Bears say
Cingulate is experiencing significant leadership changes, with the CEO being placed on administrative leave and returning after resolving personal issues, which may negatively impact operations. While the company's focus on using its Precision Timed Release (PTR) drug delivery platform to develop once-daily, multi-dose tablets for ADHD and anxiety has potential, it faces competition from already established approved drugs, and it remains to be seen if the platform can deliver on its promise of improved patient outcomes. Additionally, the lack of diversification in the company's pipeline may pose a risk to its long-term success.
This aggregate rating is based on analysts' research of Cingulate and is not a guaranteed prediction by Public.com or investment advice.
Cingulate (CING) Analyst Forecast & Price Prediction
Start investing in Cingulate (CING)
Order type
Buy in
Order amount
Est. shares
0 shares